Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2013 08:30 ET | Source: Mateon Therapeutics

OXiGENE Announces $5 Million Private Placement

SOUTH SAN FRANCISCO, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
March 20, 2013 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
March 12, 2013 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Full Year 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported...
March 04, 2013 14:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report...
February 06, 2013 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial

SOUTH SAN FRANCISCO, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
February 04, 2013 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation at BIO CEO Conference on February 12th

SOUTH SAN FRANCISCO, Calif., Feb. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
January 23, 2013 16:00 ET | Source: Mateon Therapeutics

OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
January 16, 2013 09:00 ET | Source: Mateon Therapeutics

OXiGENE Regains Nasdaq Closing Bid Price Compliance

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
December 10, 2012 09:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
November 21, 2012 09:00 ET | Source: Mateon Therapeutics

OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that its...